Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma, Thymic Clear all
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

NCT01621568
View directory record Official record
Conditions
Thymoma, Thymus Neoplasms
Interventions
Sunitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 24, 2026, 5:43 AM EDT
Recruiting Phase 2 Interventional

HEARTS Trial for Thoracic Cancers

NCT07132918
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
Interventions
MRgART, LINAC
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

NCT01165658
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid, Thymic Cancer, Lung Cancer
Interventions
Proton Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

NCT00198133
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Premetrexed (Alimta)
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 24, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

NCT01025089
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
8
States / cities
Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

NCT00372840
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions
educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 24, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT02146170
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage

NCT00589290
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Belinostat (PDX101)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

NCT01100944
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
PXD101with cisplatin+doxorubicin+cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

NCT01143545
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 24, 2026, 5:43 AM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

NCT01011439
View directory record Official record
Conditions
Thymic Carcinoma
Interventions
Milciclib Maleate
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 24, 2026, 5:43 AM EDT
Not listed No phase listed Observational

Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer

NCT03170804
View directory record Official record
Conditions
Thyroid Nodule, Thyroid Cancer, Thyroid Diseases, Thymic Carcinoma
Interventions
Not listed
Lead sponsor
Aventura Hospital and Medical Center
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated No phase listed Observational

Cardiac MRI Biomarker Testing (GCC 1618)

NCT02688166
View directory record Official record
Conditions
Breast Cancer, Lung Cancer (Non-Small Cell), Thoracic Cancer, Thymic Cancer, Mesothelioma
Interventions
Complete Cardiac Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 24, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

NCT04925947
View directory record Official record
Conditions
Thymic Carcinoma
Interventions
KN046
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

NCT00003662
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

NCT00369889
View directory record Official record
Conditions
Thymic Cancer, Thymoma
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

NCT00965250
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Thymic Carcinoid, Thymic Neuroendocrine Tumors
Interventions
IMC-12
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

NCT00314873
View directory record Official record
Conditions
Thymic Carcinoma
Interventions
Gleevec (imatinib)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

NCT00066404
View directory record Official record
Conditions
Cancer
Interventions
recombinant adenovirus-hIFN-beta
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 24, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

NCT04417660
View directory record Official record
Conditions
Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Interventions
M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

NCT01306045
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
Interventions
AZD6244, MK-2206, Lapatinib, Erlotinib, Sunitinib, Molecular Profiling
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 24, 2026, 5:43 AM EDT